



PERSONAL INFORMATION

Name

VALENTINA GUARNERI

Address

University of Padova
Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche
Medical Oncology 2, Istituto Oncologico Veneto IRCCS
Oncologia Medica 2, Via Gattamelata 64, 35100 Padova, Italy
valentina.guarneri@unipd.it
phone +39 049 8215291
mobile +39 342 8086635

Nationality

Italian

Medical license

LI3294, 2000

WORK EXPERIENCE AND ACADEMIC POSITIONS

- Dates (from – to) 18/01/2021-onwards
- Name and address of the employer University of Padova
Dept. of Surgery, Oncology and Gastroenterology
Istituto Oncologico Veneto IRCCS , Medical Oncology 2
- Occupation or position held Full Professor of Medical Oncology

- Dates (from – to) 01/10/2014-17/01/2021
- Name and address of the employer University of Padova
Dept. of Surgery, Oncology and Gastroenterology
Istituto Oncologico Veneto IRCCS , Medical Oncology 2
- Occupation or position held Associate Professor of Medical Oncology

- Dates (from – to) June 2017-onwards
- Name and address of the employer University of Padova
Dept. of Surgery, Oncology and Gastroenterology
Vice-Director, Medical Oncology School of Specialization

- Dates (from – to) 01/12/2018-onwards
- Name and address of the employer Istituto Oncologico Veneto IRCCS
- Occupation or position held Head of the “Network Clinical Trial” Unit

- Dates (from – to) 01/04/2013-01/10/2014
- Name and address of the employer University of Padova
Dept. of Surgery, Oncology and Gastroenterology
Istituto Oncologico Veneto IRCCS, Medical Oncology 2
- Occupation or position held Assistant Professor of Medical Oncology

- Dates (from – to) 01/09/2013-30/11/2018
- Name and address of the employer Istituto Oncologico Veneto IRCCS
Oncologia Medica 2
- Occupation or position held Head of the “Translational Research and Innovative Therapy” Unit

- Dates (from – to) 11/2005 - 31/03/2013
- Name and address of the employer Division of Medical Oncology,
University of Modena and Reggio Emilia, Modena University Hospital
- Occupation or position held Assistant Professor

- Dates (from – to) 05/2011 - 31/03/2013
- Name and address of the employer Division of Medical Oncology,
Modena University Hospital
- Occupation or position held Coordinator of the Breast Unit

- Dates (from – to) 09-12/2009
- Name and address of the employer University of Texas MD Anderson Cancer Center, Dept of Breast Medical Oncology
- Occupation or position held Visiting Assistant Professor

- Dates (from – to) 01-07/2005
- Name and address of the employer University of Texas MD Anderson Cancer Center, Dept of Breast Medical Oncology
- Occupation or position held Observer

- Dates (from – to) 2003-2005
- Name and address of the employer Modena University Hospital, Division of Oncology
- Occupation or position held Attending Physician

- Dates (from - to) 11/2003-11/2005
- Name and type of organisation University of Modena and Reggio Emilia
- Principal subjects/occupational skills covered Clinical Oncology
- Title of qualification awarded Adjunct Professor

- Dates (from – to) 1999-2003
- Name and address of the employer Pisa University Hospital
- Occupation or position held Post-graduate Specialization, Medical Oncology

EDUCATION AND TRAINING

- Dates 2013-2014
- Name and type of organisation providing education and training Scuola di Direzione Aziendale Università Bocconi, Milano
- Title of qualification awarded Participation to the course “Programme for Oncology Leadres in Europe”

- Dates 2006-2007
- Name and type of organisation providing education and training University of Modena and Reggio Emilia, Modena, Italy
- Title of qualification awarded post-graduation degree on "Statistics applied to clinic"

- Dates 2004-2006
- Name and type of organisation providing education and training University of Modena and Reggio Emilia, Modena, Italy
- Principal subjects/occupational skills covered Breast cancer clinical trials with biomarker evaluation
- Title of qualification awarded Ph.D. Clinical and Experimental Oncology
- Dates 1999-2003
- Name and type of organisation providing education and training Pisa University, Italy
- Title of qualification awarded Specialty Clinical Oncology, graduated 110/110 cum laude
- Date 2000
- Title of qualification awarded Italian Medical Licensure
- Dates 1993-1999
- Name and type of organisation providing education and training Pisa University, Italy
- Title of qualification awarded M.D. degree 110/110 cum laude
- Date 1993
- Name and type of organisation providing education and training Liceo-Ginnasio GB Niccolini-FD Guerrazzi, Livorno, ITALY
- Title of qualification awarded Humanistic Bachelor Degree 60/60

MOTHER TONGUE **Italian**

OTHER LANGUAGES

- English**
- Reading skills EXCELLENT
 - Writing skills EXCELLENT
 - Verbal skills EXCELLENT

ANNEXES

Formal Teaching
 Research Activity
 Committee
 Awards
 Scientific Affiliations
 Editorial Reviewer Board
 Scientific Publications
 Presentations at National and International Conferences

Formal Teaching

- Clinical Oncology, School of Medicine, University of Padova
- Clinical Oncology Speciality School, University of Padova
- Clinical Biochemistry Speciality School, University of Padova
- Endocrinology and Metabolic Disorders Speciality School, University of Padova
- General Surgery Specialty School, University of Padova
- Gastroenterology Specialty School, University of Padova
- Hematology Specialty School, University of Padova
- Post Doctoral Fellowship in Oncology and Surgical Oncology, University of Padova

Research activity

Since 2001, Dr Guarneri is involved in breast cancer clinical and translational research. The major research accomplishments are:

The evaluation of the prognostic role of pathologic complete remission (pCR) after neoadjuvant chemotherapy in more than 1200 patients treated at the MD Anderson Cancer Center, Houston, TX. We have demonstrated that pCR is prognostic, independently from the expression of hormone receptor (Guarneri V et al, J Clin Oncol. 2006; 24:1037-1044, PMID: 16505422). This observation was recently confirmed by a meta-analysis on more than 12000 cases.

The study of the dynamic change in the expression of hormone receptor and Her2. We have demonstrated a change in the expression of HR and HER2 from primary tumors to metastatic deposits (Guarneri et al, The Oncologist, 13:838-44, 2008 PMID: 18650259) and the correlation of the change in receptor status with survival (Dieci et al, Ann Oncol. 2013 Jan;24(1):101-8. PMID: 23002281.2013). In the neoadjuvant setting, we have demonstrated that the loss of HER2 expression is more frequent after chemotherapy than after chemotherapy + anti-Her2 agents. (Guarneri et al, Ann Oncol. 2013 Dec;24(12):2990-4. PMID: 24013581)

The generation of a prognostic model based on the study of residual disease after neoadjuvant chemotherapy. We have demonstrated that patients with less than pCR have a different risk of relapse according to Ki67 and nodal status after therapy. (Guarneri V et al, Ann Oncol, Jul;20(7):1193-8, 2009, PMID: 19221152).

The role of dual anti-Her2 blockade in the neoadjuvant setting. We have demonstrated that the combination of trastuzumab, lapatinib and chemotherapy significantly increases the rate of pCR as compared to chemotherapy plus either single agent alone in patients with Her2 positive stage II-III breast cancer. (Guarneri V et al, J Clin Oncol, 2012).

The association between PI3KCA mutations and response to letrozole-lapatinib. In a randomized phase II study of neoadjuvant letrozole-lapatinib vs letrozole-placebo, the probability of achieving an objective response in the letrozole-lapatinib arm was higher in the presence of PI3KCA mutations vs wild type cases. In the letrozole-placebo arm, the objective response rate was not influenced by PI3KCA status. (Guarneri V et al, J Clin Oncol. 2014)

Development of a de-escalating strategy and biomarker evaluation in Her2 positive BC (Guarneri et al, oral presentation ASCO 2018, Ann Oncol 2018, Conte P et al, Ann Oncol 2019, Guarneri et al Clin Cancer Res 2020)

Below are detailed the principal research grants:

Principal Investigator: Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network: The ROVID Study (Finanziamento **Fondazione Cariparo, 2020**).

- Principal Investigator: Budget impact and clinical outcome of innovative drugs in oncology. The Renew project (Finanziamento nell'ambito di collaborazione pubblico-privata per progetti di ricerca, innovazione e formazione in Sanità, **Regione Veneto-CORIS**, bando **2018**)

- Principal Investigator: Monitoring peripheral immune blood cells as predictor of efficacy and toxicity in patients with solid tumors treated with checkpoint inhibitors, **Istituto Oncologico Veneto 5X1000 2019**

- Principal Investigator Progetto Ricerca **Finalizzata Ministeriale GR-2013-02356771** "Challenging the role of chemotherapy in HER2 positive early breast cancer: PI3KCA pathways alteration and response to neoadjuvant pertuzumab-trastuzumab plus letrozole or paclitaxel in Hormone Receptor positive-HER2 positive breast cancer patients."

- Principal Investigator **progetto AIRC** "PIK3CA mutations/PTEN loss and infiltrating tumor lymphocytes to personalize therapy in HER2+ early breast cancer" **MFAG 2014** Id.15938

- Principal Investigator progetto "Monitoring peripheral immune blood cells as predictors of efficacy and toxicity in patients with lung cancer treated with checkpoint inhibitors " (Ricerca Scientifica fondi **DOR 2020**- codice DOR2087542/20, Unipd)

- Principal Investigator progetto " Radiomics surrogates for molecular response after short-term letrozole for patients with operable HER2+/HR+ breast cancer" (Ricerca Scientifica fondi **DOR 2019**-codice DOR1987531/19, Unipd)

- Principal Investigator progetto "Body mass-index as a prognostic factor for patients with early breast cancer: a single-Institution analysis with long-term follow up." (Ricerca Scientifica fondi **DOR 2018**- codice DOR1822514/18, Unipd)

- Principal Investigator progetto "Prognostic and predictive factors in breast cancer patients treated with neoadjuvant therapy (Ricerca Scientifica fondi **DOR 2017**- codice DOR1725090/17, Unipd)

- Principal Investigator progetto "Prognostic and predictive factors in breast cancer patients treated with neoadjuvant therapy (Ricerca Scientifica fondi **DOR 2016**- codice 1642729/16, Unipd)

- Principal Investigator progetto "Prognostic and predictive factors in breast cancer patients treated with neoadjuvant therapy" (Ricerca Scientifica fondi **quota EX 60% - Bando 2015** 60A07-8815, Unipd)

- Principal Investigator progetto "PIK3CA mutations and survival in HER2-positive breast cancer

patients treated with neoadjuvant trastuzumab and lapatinib" (Ricerca Scientifica fondi **quota EX 60% - Bando 2014** 60A07-9077, Unipd)

- Principal Investigator progetto "Neoadjuvant therapy for operable breast cancer: a model to personalize cancer therapy" (Ricerca Scientifica fondi quota **EX 60% - Bando 2013** 60A07-7808, Unipd)

investigator progetto "Recidiva di carcinoma mammario: caratterizzazione del profilo molecolare/immunologico e confronto con la neoplasia primitiva" (**Ricerca Corrente IOV LP254A, 2018**)

- Principal Investigator progetto "Terapia neoadiuvante del carcinoma mammario a recettori ormonali positivi-her2 positivo: identificazione di marcatori predittivi e prognostici" (**Ricerca Corrente IOV L02P47, 2013**)

- Principal Investigator progetto "Studio della malattia residua dopo terapia neoadiuvante nel carcinoma mammario operabile" (**Ricerca Corrente IOV L02P38, 2013**)

- Principal Investigator progetto "Significato prognostico dello stato mutazionale di PI3KCA in pazienti affette da carcinoma mammario HER2 positivo trattate con chemioterapia e trastuzumab adiuvante nel protocollo SHORT-HER" (**Ricerca Corrente IOV L02P36, 2013**)

- Principal Investigator progetto "Ricaratterizzazione biologica del carcinoma mammario metastatico: implicazioni prognostiche e terapeutiche nell'era della medicina personalizzata" (**Ricerca Corrente IOV L02P33, 2013**)

- Principal Investigator progetto "Impatto del sottotipo molecolare e del trattamento locoregionale in pazienti con carcinoma mammario e metastasi cerebrali" (**Ricerca Corrente IOV L02P16, 2013**)

- Co-investigator Progetto **Ministero della Salute RF-2009-1472600**

- Co-investigator **Programma di Ricerca Regione Emilia Romagna-Universita` 2007/2009** , Area 1- Ricerca Innovativa

- Co-investigator e membro dello steering committee: "Short-HER: multicentric randomised phase III trial of 2 different adjuvant chemotherapy regimens plus 3 vs 12 months of trastuzumab in HER2 positive breast cancer patients". Finanziamento Agenzia Italiana del Farmaco (**AIFA-2006-2009**)

- Co-Investigator: Primary systemic therapy for early breast cancer: clinical, biological and molecular outputs" (**PRIN 2005-2007**, project #2005067951).

- Co-investigator: "Proteomic, genomic and biomarker expression as predictor of response to chemotherapy and molecularly targeted agents in breast cancer patients treated with preoperative therapy." **Progetti Integrati Oncologia 2006** (project 04/07).

- Co-investigator: "Operable Breast Cancer: an in vivo model to integrate target directed therapies in the management of operable breast cancer" (**grant AIRC 2003-2004**)

Prof Guarneri has extensive experience as PI or co-investigator of clinical trial conduct. She has GCP certification.

Committee

- Italian Ministry of Health Research Committee 2015-2017
- ESMO OncologyPRO Working Group: 2015-2017
- ESMO Fellowship & Award Committee: 2015-2017
- ESMO Young Oncologists Committee 2010-2012, renewed 2012-2014
- ESMO E-learning and CME Working Group: 2012-2014
- 2010-2016 member of the International Congress on Anticancer Treatment (ICACT) Scientific Committee
- AIOM National Congress Scientific Committee: 2010; 2012,2018,2019

Awards

- 2001 Award from Ordine dei Medici di Livorno for the best MD degree thesis
- 2004: Research grant from Komen foundation Italy- Università Cattolica del Sacro Cuore di Roma for research project to be completed at the University of Texas, MD Anderson Cancer Center, Houston, Texas (Prof GN Hortobagyi)
- 2004: Research award from Lega Italiana per la Lotta contro i Tumori
- 2005: Young Researcher Award from "Associazione Malati Oncologici"
- 2006: Young Researcher Award from voluntary association "Cestodiciliege"
- 2007: Young Researcher Award from voluntary association "Cestodiciliege"
- 2009: Travel Grant from "Fondazione Komen" ("Prognostic role of Ki67 following preoperative chemotherapy" - MD Anderson Cancer Center, Houston, Texas)
- 2010: Awardee of the "Unimore Monica Boscolo Research Grant" (Residual tumor after preoperative chemotherapy in breast cancer as a model to study resistant micrometastatic disease)

- 2013: Young Researcher Award, Fondazione Guido Berlucchi
- 2013 Marco Venturini Lecture, Italian Association of Medical Oncology (AIOM)

Scientific Affiliations

- Italian Association Medical Oncology (AIOM)
- European Society Medical Oncology (ESMO)
- American Society Clinical Oncology (ASCO)
- EBMT (European Bone Marrow Transplantation)

Editorial Reviewer Board

Annals of Oncology, Clinical Cancer Research, The Oncologist, Breast Cancer Research, British Journal of Cancer, BMC Cancer, Clinical Breast Cancer, Annals of Surgical Oncology, American Journal of Clinical Oncology, Cancer Letters, Expert Opinion on Drug Safety, Expert Review of Anticancer Therapy, Expert opinion on Pharmacotherapy, Cancer Chemotherapy and Pharmacology, International Journal of Biomedical Science, Chemotherapy, Oncology, Journal of Oncology, Lancet Oncology

Presentations at National and International Conferences

Prof Guarneri has presented more than 3000 invited lectures at National meetings, and more than 80 presentations at International Meetings.

Publications:

Author or co-author of 168 full-text paper in peer-reviewed journals. Total Impact Factor: 1212, IF as first or last author: 524 (JCR-ISI WEB 2019). Scopus H index 35, total citations 5300 as of January 2021.

She is author and co-authors of several book chapters.

Publication list:

1. Dieci MV, Miglietta F, **Guarneri V**. Immune infiltrates in breast cancer: recent updates and clinical implications. **Cells**, in press (**IF 4.366**)
2. Danesi R, Fogli S, Indraccolo S, Del Re M, Dei Tos AP, Leoncini L, Antonuzzo L, Bonanno L, Guarneri V, Pierini A, Pi Conte PF, Amunni G. Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. **ESMO Open**, in press (**IF 5.329**)
3. **Guarneri V**, Bassan F, Zagonel V, Milella M, Zaninelli M, Cattelan AM, Vianello A, Gori S, Aprile G, Azzarello G, Chiari R, Favaretto A, Oliani C, Scola A, Pastorelli D, Mandarà M, Zustovich F, Bernardi D, Chiarion-Sileni V, Morandi P, Toso S, Di Liso E, Zampieri³, Caccese M, Zampiva I, Puccetti O, Celestino M, Dieci MV², Conte P. Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network: The ROVID Study², *on behalf of the Veneto Oncology Network*. **EUR J Cancer**, in press (**IF 7.275**)
4. Griguolo G, Dieci MV, Paré L, Miglietta F, Generali DG, Frassoldati A, Bisagni G, Piacentini F, Tagliafico E, Cagossi K, Ficarra G, Prat A, Conte P, **Guarneri V**. Immune microenvironment of hormone receptor-positive/HER2-negative breast cancer and tumor biology. **npj Breast Cancer**, in press (**IF 6.000**)
5. Berardi R, Torniai M, Cona MS, Cecere F, Chiari R, **Guarneri V**, La Verde N, Locati L, Lorusso D, Martinelli E, Garassino M. On behalf of Women for Oncology Italy. COVID19 and gender gap in Italy. **ESMO Open**, in press (**IF 5.329**)
6. Pavan A, Boscolo Bragadin A, Calvetti L, Ferro A, Zulato E, Nardo G, Attili I, Dal Maso A, Frega S, Menin AG, Fassan M, Calabrese F, Pasello G, **Guarneri V**, Aprile G, Conte PF, Indraccolo S, Bonanno L. Role of Next generation sequencing-based liquid biopsy in advanced Non-small cell lung cancer patients treated with immune checkpoint inhibitor: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. **Translational Lung Cancer Research**, in press (**IF 5.132**) **contato nel 2020**
7. Tasca G, Dieci MV, Baretta Z, Faggioni G, Nicoletto MO, Peccatori F, **Guarneri V**, Colombo N. Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center. **Front Oncol**. 2020 Dec 14;10:608783. doi: 10.3389/fonc.2020.608783. eCollection 2020 (**IF 4.848**)

8. Thanopoulou E, Khader L, Wardley A, Ettl J, Miglietta F, Neven P, **Guarneri V**. Therapeutic strategies for the management of hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer: a review of the current literature. *Cancers (Basel)*. 2020 Nov 10;12(11):3317. doi: 10.3390/cancers12113317. (IF 6.126)
9. Zarrilli G, Businelo G, Dieci MV, Paccagnella S, Carraro V, Cappellesso R, Miglietta F, Griguolo G, **Guarneri V**, Lo Mele M, Fassan M. The tumor microenvironment of primitive and metastatic breast cancer: implications for novel therapeutic strategies. *Int J Mol Sci*. 2020 Oct 30;21(21):8102. doi: 10.3390/ijms21218102. (IF 4.556)
10. Strauss L, **Guarneri V**, Gennari A, Sica A. Implications of Metabolism-Driven Myeloid Dysfunctions in Cancer Therapy. *Cell Mol Immunol*. 2020 Oct 19:1-13. doi: 10.1038/s41423-020-00556-w. Online ahead of print. (IF 8.484)
11. Dieci MV, **Guarneri V**. Should triple-positive breast cancer be recognized as a distinct subtype? *Expert Rev Anticancer Ther*. 2020 Dec;20(12):1011-1014. doi: 10.1080/14737140.2020.1829484. Epub 2020 Oct 6. (IF 3.573)
12. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Rodriguez JLM, Campone M, Hamilton E, Sohn J, **Guarneri V**, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, for the monarchE committee members and Investigators. Abemaciclib in node-positive, high risk early breast cancer. *J Clin Oncol* 2020 Sep 20;JCO2002514. doi: 10.1200/JCO.20.02514. Online ahead of print. (IF: 32.956)
13. Boscolo A, Fortarezza F, Lunardi F, Comacchio G, Urso L, Frega S, Menis J, Bonanno L, **Guarneri V**, Rea F, Conte PF, Calabrese F, Pasello G. Combined immunoscore for prognostic stratification of early stage Non-Small Cell Lung Cancer. *Front Oncol*. 2020 Sep 25;10:564915. doi: 10.3389/fonc.2020.564915. eCollection 2020. (IF 4.848)
14. Attili I, Bonanno L, Karachaliou N, Bracht JWP, Berenguer J, Codony Servat C, Codony Servat J, Aldeguer E, Gimenez Capitan E, Dal Maso A, Fassan M, Chaib I, Miguel Angel Molina-Vila MA, Passaro A, de Marinis F, Pasello G, **Guarneri V**, Conte PF, Rosell R. SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated NSCLC. *Transl Lung Cancer Res*. 2020 Oct;9(5):1810-1821. doi: 10.21037/tlcr-20-681. (IF 5.132)
15. Di Liso E, Bottosso M, Lo Mele M, Tsvetkova V, Dieci MV, Falci C, Faggioni G, Tasca G, Giorgi CA, Giarratano T, Mioranza E, Michieletto S, Saibene T, Dei Tos AP, Conte PF, **Guarneri V**. Prognostic factors in phyllodes tumors of the breast: a retrospective study on 166 consecutive cases. *ESMO Open*. 2020 Oct;5(5):e000843. doi: 10.1136/esmoopen-2020-000843. (IF 5.329)
16. Griguolo G, Brasó-Maristany F, González-Farré B, Pascual T, Chic N, Sauri T, Kates R, Gluz O, Martínez D, Paré L, Tsvetkova V, Pesantez D, Vidal M, Adamo B, Muñoz M, Galván P, Barberá B, Cuatrecasas M, Christgen M, Kreipe H, Monge-Escartín I, Villagrasa P, Soy D, Giarratano T, Dieci MV, Conte PF, Harbeck N, **Guarneri V**, Prat A. ERBB2 mRNA expression and response to ado-trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. *Cancers (Basel)*. 2020 Jul 14;12(7):1902. doi: 10.3390/cancers12071902. (IF 6.126)
17. Prat A, **Guarneri V**, Paré L, Griguolo G, Pascual T, Dieci MV, Chic N, González-Farré B, Frassoldati A, Sanfeliu E, Cejalvo JM, Muñoz M, Bisagni G, Brasó-Maristany F, Urso L, Vidal M, Brandes AA, Adamo B, Musolino A, Conte B, Oliveira M, Saura C, Pernas S, Alarcón J, Llombart-Cussac A, Cortés J, Manso L, López R, Ciruelos E, Schettini F, Villagrasa P, Carey LA, Perou CM, Piacentini F, Tagliafico E, Parker JS, Conte PF. A multi-parameter prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer. *Lancet Oncol*. 2020 Nov;21(11):1455-1464. doi: 10.1016/S1470-2045(20)30450-2. (IF 33.752)
18. **Guarneri V**, Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotto F, Rimanti A, Garrone O, Bertone E, Cagossi K, Nanni O, Piacentini F, Orvieto E, Griguolo G, Curtarello M, Urso L, Paré L, Chic N, D'Amico R, Prat A, Pierfranco Conte PF. PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype. *Clin Cancer Res*, 2020 Aug 25;clinres.1731.2020. doi: 10.1158/1078-0432.CCR-20-1731. Online ahead of print. (IF 10.107)
19. Vernaci GM, Meroni M, Dieci MV, Saibene T, Montesco MC, Orvieto E, Cattelan A, Ghiotto C, Miglietta F, Guarneri V, Cagol M. Post-surgical pyoderma gangrenosum in a breast cancer patient: a case report and literature review. *Case Reports in Oncology*, 2020 in press

20. Miglietta F, Tsvetkova V, Dieci MV, Griguolo G, Vernaci G, Menichetti A, Falci C, Faggioni G, Giarratano T, Frezzini S, Mioranza E, Lo Mele M, Conte PF, **Guarneri V**. Validation of Residual Proliferative Cancer Burden (RPCB) as a predictor of long-term outcome following neoadjuvant chemotherapy in hormone-receptor (HR)-positive/HER2-negative breast cancer patients. **The Oncologist**, 2020 Jul 3. doi: 10.1634/theoncologist.2020-0201. Online ahead of print. **(IF 5.025)**
21. Dieci MV, Miglietta F, Griguolo G, **Guarneri V**. Biomarkers for HER2-positive metastatic breast cancer: beyond hormone receptors. **Cancer Treatment Reviews**, Volume 88, August 2020, 102064. <https://doi.org/10.1016/j.ctrv.2020.102064> **(IF 8.885)**
22. Bonanno L, Pavan A, Ferro A, Calvetti L, Frega S, Pasello G, Aprile G, **Guarneri V**, Conte PF. Clinical impact of plasma and tissue Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC): a real-world experience. **The Oncologist** 2020 Jun 18. doi: 10.1634/theoncologist.2020-0148. Online ahead of print. **(IF 5.025)**
23. Poortmans PM, **Guarneri V**, Cardoso MJ. Cancer and COVID-19: what do we really know? **Lancet**. 2020 May 29:S0140-6736(20)31240-X. doi: 10.1016/S0140-6736(20)31240-X. **(IF 60.392)** Invited comment
24. Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Tasca G, Giorgi CA, Cumerlato E, Massa D, Lo Mele M, Orvieto O, **Guarneri V***, Conte PF. Integration of TILs, PD-L1, CD8 and FOXP3 in prognostic models for triple negative breast cancer: analysis of 244 stage I-III patients treated with standard therapy. **Eur J Cancer**, 2020 Jul 1;136:7-15. doi: 10.1016/j.ejca.2020.05.014. Online ahead of print (*corresponding author) **(IF 7.275)**
25. Pasello G, Pavan A, Attili I, Bortolami A, Bonanno L, Menis J, Conte PF, **Guarneri V**. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. **Cancer Treatment Reviews**, 2020 doi <https://doi.org/10.1016/j.ctrv.2020.102031> **(IF 8.885)**
26. Zulato E, Attili I, Pavan A, Nardo G, Del Bianco P, Boscolo Bragadin A, Verza M, Pasqualini L, Pasello G, Fassan M, Calabrese F, **Guarneri V**, Amadori A, Conte P, Indraccolo S, Bonanno L. Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. **Br J Cancer**. 2020 May 7. doi: 10.1038/s41416-020-0833-7. **(IF 5.791)**
27. Griguolo G, Dieci MV, Miglietta F, **Guarneri V**, Conte P. Olaparib for advanced breast cancer. **Future Oncol**. 2020 Apr 6. doi: 10.2217/fon-2019-0689. PubMed PMID: 32249603. **(IF 2.66)**
28. Caputo R, Cazzaniga ME, Sbrana A, Torrisi R, Paris I, Giordano M, Montesarchio V, **Guarneri V**, Amaducci L, Bilancia D, Cilenti G, Fabi A, Collovà E, Schirone A, Bonizzoni E, Celio L, De Placido S, De Laurentiis M. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. **BMC Cancer**. 2020 Mar 19;20(1):232. doi: 10.1186/s12885-020-6707-9. PubMed PMID: 32188417; PubMed Central PMCID: PMC7081578. **(IF 3.15)**
29. Frega S, Ferro A, Bonanno L, **Guarneri V**, Conte PF, Pasello G. Lung cancer in HIV-positive patients: pathogenic features and implications for treatment. **Int J Mol Sci**. 2020 Feb 26;21(5). pii: E1601. doi: 10.3390/ijms21051601. Review. PubMed PMID: 32111093; PubMed Central PMCID: PMC7084664. **(IF 4.556)**
30. Lorusso D, Bologna A, Cecere SC, De Matteis E, Scandurra G, Zamagni C, Arcangeli V, Artioli F, Bella M, Blanco G, Cardalesi C, Casartelli C, De Vivo R, Di Napoli M, Gisone EB, Lauria R, Lissoni AA, Loizzi V, Maccaroni E, Mangili G, Marchetti C, Martella F, Naglieri E, Parolin V, Ricciardi G, Ronzino G, Salutari V, Scarfone G, Secondino S, Spagnoletti I, Tasca G, Tognon G, **Guarneri V**. Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel. **Support Care Cancer**. 2020 Feb 11;10.1007/s00520-020-05320-4. doi: 10.1007/s00520-020-05320-4. Epub ahead of print. PMID: 32048043. **(IF 2.635)**
31. Carbognin L, Simbolo M, Calì A, Vicentini C, Delfino P, Sperduti I, Fassan M, Schettini F, Dieci MV, Griguolo G, Pilotto S, Fiorio E, Arpino G, **Guarneri V**, De Placido S, Conte P, Manfrin E, Brunelli M, Scambia G, Scarpa A, Tortora G, Bria E. Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. **The Breast**. 2020 Jan 27;50:56-63. doi: 10.1016/j.breast.2020.01.034. Epub ahead of print. PMID: 32028173. **(IF 3.754)**
32. Schettini F, Pascual T, Conte B, Chic N, Brasó-Maristany F, Galván P, Martínez O, Adamo B, Vidal M, Muñoz M,

- Fernández-Martínez A, Rognoni C, Griguolo G, **Guarneri V**, Conte PF, Locci M, Brase JC, Gonzalez-Farre B, Villagrasa P, De Placido S, Schiff R, Veeraraghavan J, Rimawi MF, Osborne CK, Pernas S, Perou CM, Carey LA, Prat A. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. **Cancer Treat Rev.** 2020 Mar;84:101965. doi: 10.1016/j.ctrv.2020.101965. Epub 2020 Jan 17. PMID: 32000054. (IF 8.885)
33. **Guarneri V**, Pronzato P, Bertetto O, Roila F, Amunni G, Bortolami A, Tognazzo S, Griguolo G, Pagano E, Stracci F, Bianconi F, Gemmi F, Bachini L, Ciccone G, Paoli G, Paleari L, Conte PF. Use of electronic administrative databases to measure quality indicators of breast cancer care: the experience of five regional oncology networks in Italy. **J Oncol Pract.** 2019 Dec 19;JOP1900466. doi: 10.1200/JOP.19.00466. [Epub ahead of print] (IF 3.551)
 34. Giarratano T, Frezzini S, Zanoocco M, Giorgi CA, Mioranza E, Miglietta F, Griguolo G, Falci C, Faggioni G, Tasca G, Di Liso E, Vernaci G, Menichetti A, Mantiero M, Grosso D, **Guarneri V**, Dieci MV. Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study. **Breast J.** 2019 Dec 14. doi: 10.1111/tbj.13711. [Epub ahead of print] PubMed PMID: 31837103. (IF 1.991)
 35. Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Giotta F, Aieta M, Gebbia V, Musolino A, Garrone O, Donadio M, Rimanti A, Beano A, Zamagni C, Soto Parra H, Piacentini F, Danese S, Ferro A, Cagossi K, Sarti S, Gambaro AR, Romito S, Russo A, Amaducci L, Balduzzi S, Vicini R, D'Amico R, Griguolo G, **Guarneri V**, Conte PF. Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. **BMC Med.** 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z (IF 6.782)
 36. Hurvitz SA, Martín M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, **Guarneri V**, Huang CS, Barriga S, Wijayawardana SR, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ. Potent cell cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, Phase 2 neoadjuvant study in HR+/HER2- breast cancer. **Clin Cancer Res.** 2020 Feb 1;26(3):566-580. doi: 10.1158/1078-0432.CCR-19-1425. Epub 2019 Oct 15. (IF 10.107)
 37. Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, **Guarneri V**, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S. BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. **Diagnostics** (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146. PubMed PMID: 31600986. (IF 3.110)
 38. Sica A, **Guarneri V**, Gennari A. Myelopoiesis, Metabolism and Therapy: a crucial crossroads in cancer progression. **Cell Stress.** 2019 Jul 1;3(9):284-294. doi:10.15698/cst2019.09.197.
 39. Miglietta F, Griguolo G, **Guarneri V**, Dieci MV. Programmed cell death ligand 1 (PD-L1) in breast cancer: technical aspects, prognostic implications and predictive value. **The Oncologist.** 2019 Nov;24(11):e1055-e1069. doi: 10.1634/theoncologist.2019-0197. Epub 2019 Aug 23 (IF 5.025)
 40. Pavan A, Attili I, Pasello G, **Guarneri V**, Conte PF, Bonanno L. Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges. **J Immunother Cancer.** 2019 Aug 5;7(1):205. doi: 10.1186/s40425-019-0690-1 (IF 9.913)
 41. Vernaci G, Dieci MV, Manfrin S, Mantiero M, Falci C, Faggioni G, Mioranza E, Menichetti A, Tasca G, Griguolo G, Miglietta F, Di Liso E, Saibene T, Michieletto S, Ghiotto C, Conte P, **Guarneri V**. BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. **Breast.** 2019 Oct;47:77-84. doi: 10.1016/j.breast.2019.07.003. Epub 2019 Jul 20 (IF 3.754)
 42. Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Mantiero M, Tasca G, Cumerlato E, Giorgi CA, Giarratano T, Faggioni G, Falci C, Vernaci G, Menichetti A, Mioranza E, Di Liso E, Frezzini S, Saibene T, Orvieto O, **Guarneri V**. Androgen Receptor expression and association with distant disease-free survival in triple negative breast cancer: analysis of 263 patients treated with standard therapy for stage I-III disease. **Front Oncol.** 2019 Jun 6;9:452. doi: 10.3389/fonc.2019.00452 (IF 4.848)
 43. Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, **Guarneri V**, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives". **Crit Rev Oncol Hematol.** 2019 May 25;140:67-72. (IF 5.833)

44. Dieci MV, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian PL, Oliani C, Gori S, Giarratano T, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte PF. Impact of 21-gene Recurrence Score® on treatment decision for T1-3 N0-1 ER+/HER2+ breast cancer patients: final results of the prospective multicentric ROXANE study. *The Oncologist*. 2019 May 31. pii: theoncologist.2019-0103. doi: 10.1634/theoncologist.2019-0103. [Epub ahead of print] **(IF 5.025)**
45. Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, **Guarneri V**, Aprile G, Conte P, Bonanno L. Peripheral blood markers identify risk of immune related toxicity in advanced Non-small cell lung cancer treated with immune-checkpoint inhibitors. ***Oncologist***. 2019 Aug;24(8):1128-1136. doi: 10.1634/theoncologist.2018-0563 **(IF 5.025)**
46. Di Liso E, Menichetti A, Dieci MV, Ghiotto C, Banzato A, Bianchi A, Pintacuda G, Padovan M, Nappo F, Cumerlato E, Miglietta F, Mioranza E, Zago G, Corti L, **Guarneri V**, Conte P. Neoplastic Pericardial Effusion: A Monocentric Retrospective Study. *J Palliat Med*. 2019 Mar 19. doi: 10.1089/jpm.2018.0491. **(IF 2.085)**
47. **Guarneri V**. Enthuse for PERUSE: when clinical judgement overcomes regulatory boundaries.. *Ann Oncol*. 2019 May 1;30(5):665-667. doi: 10.1093/annonc/mdz091. **(IF: 18.274)**
48. Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Conte PF, Schiff R, **Guarneri V**, Kent Osborne C, Rimawi MF. A combined biomarker based on PAM50 HER2-enriched subtype and ERBB2 mRNA predicts response and survival following HER2 blockade without chemotherapy in HER2-positive breast cancer. *J Natl Cancer Inst*. 2019 Apr 30. pii: djz042. doi: 10.1093/jnci/djz042 **(IF 11.577)**
49. Griguolo G, Pascual T, Dieci MV, **Guarneri V**, Prat A. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. *J Immunother Cancer*. 2019 Mar 29;7(1):90. doi: 10.1186/s40425-019-0548-6. **(IF 9.913)**
50. Pasello G, Vicario G, Zustovich F, Oniga F, Gori S, Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C, Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M, Menis J, Corte DD, Frega S, **Guarneri V**, Conte P. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). *Oncologist*. 2019 Jun;24(6):e318-e326. doi: 10.1634/theoncologist.2018-0712. **(IF 5.025)**
51. **Guarneri V**, Dieci MV, Bisagni G, Frassoldati A, Bianchi GV, De Salvo GL, Orvieto E, Urso L, Pascual T, Paré L, Galván P, Ambroggi M, Giorgi CA, Moretti G, Griguolo G, Vicini R, Prat A, Conte PF. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study". *Ann Oncol*. 2019 Jun 1;30(6):921-926. doi: 10.1093/annonc/mdz055. **(IF: 18.274)**
52. Gadducci A, **Guarneri V**, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutati V. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. *J Ovarian Res*. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6 **(IF 2.367)**
53. Dieci MV, Conte P, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Maiorana A, Orvieto E, Sanders M, Miglietta F, Balduzzi S, D'Amico R, **Guarneri V**. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. *Ann Oncol*. 2019 Jan 17. doi: 10.1093/annonc/mdz007. **(IF: 13.926)** [Epub ahead of print]
54. Bonanno L, Pavan A, Attili I, Pasello G, **Guarneri V**. Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy. *J Thorac Oncol*. 2019 Jan;14(1):e5-e7. doi: 10.1016/j.jtho.2018.08.2033. **(IF 10.340)**
55. Giarratano T, Miglietta F, Giorgi CA, Tsvetkova V, Michieletto S, Evangelista L, Polico I, Dieci MV, **Guarneri V**. Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary. *Front Oncol*. 2018 Dec 3;8:581. doi: 10.3389/fonc.2018.00581. eCollection 2018. **(IF 4.416)**

56. Dieci MV, Vernaci G, **Guarneri V**. Escalation and De-escalation in HER2 positive early breast cancer. *Curr Opin Oncol*, 2019 Jan;31(1):35-42.i (IF 3.653)
57. Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, **Guarneri V**. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. *Ann Oncol* 2018 Sep 13. doi: 10.1093/annonc/mdy414. [Epub ahead of print] (IF: 13.926)
58. Pelizzari G, Arpino G, Biganzoli L, Cinieri S, De Laurentiis M, Del Mastro L, Di Leo A, Gori S, **Guarneri V**, Marchetti P, Puglisi F. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. *BMC Cancer* 2018 Sep 27;18(1):932. doi: 10.1186/s12885-018-4843-2 (IF 3.288)
59. Griguolo G, Pouderoux S, Dieci MV, Jacot W, Bourgier C, Miglietta F, Firmin N, Conte PF, Viala M, **Guarneri V**, Darlix A. Clinico-pathological and treatment-associated prognostic factors in patients with breast cancer leptomeningeal metastases in relation to tumor biology. *The Oncologist*, 2018 Aug 17. pii: theoncologist.2018-0200. doi: 10.1634/theoncologist.2018-0200. [Epub ahead of print] (IF 5.306)
60. Bonanno L, Pavan A, Dieci M V, Di Liso E, Schiavon M, Comacchio G, Attili I, Pasello G, Calabrese F, Rea F, Favaretto A, Ruggie M, **Guarneri V**, Fassan M, Conte PF. The role of immune microenvironment in small-cell lung cancer: distribution of PD-L1 expression and prognostic role of FOXP3-positive tumor infiltrating lymphocytes. *Eur J Cancer*, In press (IF 7.191)
61. Frega S, Bonanno L, **Guarneri V**, Conte P, Pasello G. Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? *Crit Rev Oncol Hematol*. 2018 Aug;128:19-29. doi: 10.1016/j.critrevonc.2018.05.013. Epub 2018 May 24. (IF 4.495)
62. Mantiero M, Faggioni G, Menichetti A, Fassan M, **Guarneri V**, Conte P. Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review. *Case Rep Oncol Med* 2018 Jul 8;2018:4714708. doi: 10.1155/2018/4714708. eCollection 2018.
63. Dieci MV, Ghiotto C, Griguolo G, Barbieri C, Saccardi C, Gangemi M, Pluchinotta A, Di Liso E, Giorgi CA, Giarratano T, Tasca G, Faggioni G, Conte PF, **Guarneri V**. Patterns of fertility preservation and pregnancy outcome after breast cancer at a large comprehensive cancer center. *Journal of Women's health*, in press (IF 2.097)
64. Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, Miglietta F, Giarratano T, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, **Guarneri V**. Immune characterization of breast cancer metastases: prognostic implications. *Breast Cancer Res*. 2018 Jun 22;20(1):62. doi: 10.1186/s13058-018-1003-1. PubMed PMID:29929548. (IF 6.142)
65. Griguolo G, Dieci MV, **Guarneri V**, Conte P. Olaparib for the treatment of breast cancer. *Expert Rev Anticancer Ther*. 2018 Mar 30:1-12. doi: 10.1080/14737140.2018.1458613. [Epub ahead of print] PubMed PMID: 29582690. (IF 2.347)
66. Dieci MV, **Guarneri V**, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Olini C, Merlini L, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. *Oncologist*. 2018 Mar;23(3):297-305. doi: 10.1634/theoncologist.2017-0322. Epub 2017 Nov 13. PubMed PMID: 29133514. (IF 5.306)
67. Darlix A, Griguolo G, Thezenas S, Kantelhardt E, Thomssen C, Dieci MV, Miglietta F, Conte P, Braccini AL, Ferrero JM, Bailleux C, Jacot W, **Guarneri V**. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. *J Neurooncol*. 2018 Feb 27. doi: 10.1007/s11060-018-2805-9. [Epub ahead of print] PubMed PMID 29488184. (IF 3.06)

68. Griguolo G, Jacot W, Kantelhardt E, Dieci MV, Bourcier C, Thomssen C, Bailleux C, Miglietta F, Braccini AL, Conte P, Ferrero JM, **Guarneri V**, Darlix A. External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. **Breast**. 2018 Feb;37:36-41. doi: 10.1016/j.breast.2017.10.006. Epub 2017 Oct 23. PubMed PMID: 29073498. (IF 2.951)
69. Miglietta F, Dieci MV, Griguolo G, **Guarneri V**, Conte PF. Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? **Cancer Treat Rev**. 2017 Nov;60:100-108. doi: 10.1016/j.ctrv.2017.09.001. Epub 2017 Sep 15. Review. PubMed PMID: 28942029. (IF 8.122)
70. Banna GL, Parra HJS, Castaing M, Dieci MV, Anile G, Nicolosi M, Strano S, Marletta F, **Guarneri V**, Conte P, Lal R. Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. **Anticancer Res**. 2017 Jul;37(7):3723-3728. PubMed PMID: 28668866. (IF 1.865)
71. Carbone L, Sperduti I, Fabi A, Dieci MV, Kadrija D, Griguolo G, Pilotto S, **Guarneri V**, Zampiva I, Brunelli M, Orvieto E, Nortilli R, Fiorio E, Parolin V, Manfrin E, Calò A, Nisticò C, Pellini F, Scarpa A, Pollini GP, Conte P, Tortora G, Bria E. Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. **Breast**. 2017 Jun 16;35:21-26. doi: 10.1016/j.breast.2017.06.005. [Epub ahead of print] PubMed PMID: 28628772. (IF: 2.951)
72. Banerjee S, Califano R, Corral J, de Azambuja E, De Mattos-Arruda L, **Guarneri V**, Hutka M, Jordan K, Martinelli E, Mountzios G, Ozturk MA, Petrova M, Postel-Vinay S, Preusser M, Qvortrup C, Volkov MNM, Tabernero J, Olmos D, Strijbos MH. Professional Burnout in European Young Oncologists: Results of The European Society For Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. **Ann Oncol**. 2017 Apr 25. doi: 10.1093/annonc/mdx196. [Epub ahead of print] PubMed PMID: 28449049. (IF: 13.926)
73. Frega S, Lorenzi M, Fassan M, Indraccolo S, Calabrese F, Favaretto A, Bonanno L, Polo V, Zago G, Lunardi F, Attili I, Pavan A, Rugge M, **Guarneri V**, Conte P, Pasello G. Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. **Oncotarget**. 2017 May 16;8(20):32626-32638. doi:10.18632/oncotarget.15945. PubMed PMID: 28427238. (IF: 5.168)
74. Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T, Mastrolia I, Orvieto E, Spano C, Prapa M, Kaleci S, D'Amico R, **Guarneri V**, Dieci MV, Cascinu S, Conte P, Piacentini F, Dominici M. GD2 expression in breast cancer. **Oncotarget**. 2017 May 9;8(19):31592-31600. doi: 10.18632/oncotarget.16363. PubMed PMID: 28415563; PubMed Central PMCID: PMC5458232. (IF: 5.168)
75. Meattini I, Curigliano G, Terziani F, Becherini C, Airoidi M, Allegrini G, Amoroso D, Barni S, Bengala C, **Guarneri V**, Marchetti P, Martella F, Piovano P, Vannini A, Desideri I, Tarquini R, Galanti G, Barletta G, Livi L. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. **Med Oncol**. 2017 May;34(5):75. doi: 10.1007/s12032-017-0938-x. Epub 2017 Mar 31. Review. PubMed PMID: 28364270.
76. Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, **Guarneri V**, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). **ESMO Open**. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review. PubMed PMID: 28255451; PubMed Central PMCID: PMC5174792.
77. Evangelista L, Cervino AR, Michieletto S, Saibene T, Ghiotto C, **Guarneri V**, Conte P, Reccia P, Saladini G. Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients. **Nucl Med Commun**. 2017 Jun;38(6):537-545. doi: 10.1097/MNM.0000000000000671. PubMed PMID: 28410290. (IF: 1.495)
78. Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, **Guarneri V**. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. **Breast Cancer Res Treat**. 2017 Jun;163(2):295-302. doi:10.1007/s10549-017-4191-y. Epub 2017 Mar 13. Erratum in:

Breast Cancer Res Treat. 2017 Jun;163(3):637. PubMed PMID: 28289852. (IF: 3.605)

79. Griguolo G, Dieci MV, Giarratano T, Giorgi CA, Orvieto E, Ghiotto C, Berti F, Della Puppa A, Falci C, Mioranza E, Tasca G, Milite N, Miglietta F, Scienza R, Conte P, **Guarneri V**. Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. **J Neurooncol**. 2017 Jan;131(2):369-376. doi: 10.1007/s11060-016-2309-4. PubMed PMID:27853958. (IF 3.06)
80. Evangelista L, Dieci MV, **Guarneri V**, Conte PF. 18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature & Meta-Analysis. **Curr Radiopharm**. 2016;9(3):244-257. doi:10.2174/1874471009666161019144950. PubMed PMID: 27774910.
81. Dieci MV, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. **Ann Oncol**. 2016 Oct;27(10):1867-73. doi: 10.1093/annonc/mdw262. Epub 2016 Aug 2. PubMed PMID:27484801. (IF: 13.926)
82. Pinto C, Bella MA, Capoluongo E, Carrera P, Clemente C, Colombo N, Cortesi L, De Rosa G, Fenizia F, Genuardi M, Gori S, **Guarneri V**, Marchetti A, Marchetti P, Normanno N, Pasini B, Pignata S, Radice P, Ricevuto E, Russo A, Tagliaferri P, Tassone P, Truini M, Varesco L. Recommendations for the Implementation of BRCA Testing in the Care and Treatment Pathways of Ovarian Cancer Patients. **Future Oncology** 2016 Sep;12(18):2071-5. doi: 10.2217/fon-2016-0189. Epub 2016 May 31. (IF 2.369)
83. Loibl S, Majewski I, **Guarneri V**, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer - pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. **Ann Oncol**. 2016 May 13. pii: mdw197. [Epub ahead of print] (IF: 13.926)
84. Musolino A, Naldi N, Dieci MV, Zanoni D, Rimanti A, Boggiani D, Sgargi P, Generali D, Piacentini F, Ambroggi M, Cagossi C, Gianni L, Sarti S, Bisagni G, Ardizoni A, Conte PF, and **Guarneri V**. 'Immunoglobulin G Fragment C Receptor Polymorphisms and Efficacy of Preoperative Chemotherapy plus Trastuzumab and Lapatinib in HER2-Positive Breast Cancer. **Pharmacogenomics J**. 2016 Oct;16(5):472-7. doi: 10.1038/tpj.2016.51. Epub 2016 Jul 5. PubMed PMID:27378608 (IF 3.812)
85. Gennari R, Griguolo G, Dieci MV, **Guarneri V**, Conte PF. Fat Grafting for Breast Cancer Patients: from Basic Science to Clinical Studies. **Eur J Surg Oncol**. 2016 Aug;42(8):1088-102. doi:10.1016/j.ejso.2016.04.062. Epub 2016 May 27. Review. PubMed PMID: 27265042. (IF 3.688)
86. Dieci MV, Griguolo G, Miglietta F, **Guarneri V**. The immune system and hormone-receptor positive breast cancer: Is it really a dead end? **Cancer Treat Rev**. 2016 Mar 28;46:9-19. (IF 8.122)
87. Grisendi G, Spano C, Rossignoli F, D'souza N, Golinelli G, Fiori A, Horwitz EM, **Guarneri V**, Piacentini F, Paolucci P, Dominici M. Tumor Stroma Manipulation By MSC. **Curr Drug Targets**. 2016 Mar 7. (IF 3.112)
88. Dieci MV, Smutná V, Scott V, Yin G, Xu R, Vielh P, Mathieu MC, Vicier C, Laporte M, Drusch F, **Guarneri V**, Conte P, Delalogue S, Lacroix L, Fromigué O, André F, Lefebvre C. Whole exome sequencing of rare aggressive breast cancer histologies. **Breast Cancer Res Treat**. 2016 Feb;156(1):21-32. (IF 3.605)
89. Marinovich ML, Macaskill P, Irwig L, Sardanelli F, Mamounas E, von Minckwitz G, **Guarneri V**, Partridge SC, Wright FC, Choi JH, Bhattacharyya M, Martincich L, Yeh E, Londero V, Houssami N. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. **BMC Cancer**. 2015 Oct 8;15:662. (IF 3.288)
90. **Guarneri V**, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment with Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. **The Oncologist** 2015, 20(9):1001-10 (IF 5.306)
91. Dieci MV, **Guarneri V**. PIK3CA: a target or a marker in breast cancers. **Current Breast Cancer Reports**. 2015, 7 (3) 161-169
92. Evangelista L, Cervino AR, Ghiotto C, Saibene T, Michieletto S, Bozza F, Orvieto E, **Guarneri V**, Conte P. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer

- undergoing neoadjuvant treatment? **Eur J Nucl Med Mol Imaging**. 2015 Oct;42(11):1648-55. doi: 10.1007/s00259-015-3088-4. Epub 2015 May 31. PubMed PMID: 26025244. (IF 7.704)
93. Dieci MV, Mathieu MC, **Guarneri V**, Conte P, Delaloge S, Andre F, Goubar A. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. **Ann Oncol**. 015 Aug;26(8):1698-704. doi: 10.1093/annonc/mdv239. Epub 2015 May 20. PubMed PMID: 25995301; PubMed Central PMCID: PMC4511223. (IF 13.926)
 94. Guarneri V, Dieci MV, Bisagni G, Boni C, Cagossi K, Puglisi F, Pecchi A, Piacentini F, Conte P. Preoperative Carboplatin-Paclitaxel-Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. **Ann Surg Oncol**. 2015 Sep;22:2881-7. doi: 10.1245/s10434-015-4371-0. (IF 3.857)
 95. Fallowfield L, Guarneri V, Ozturk MA, May S, Jenkins V. Blurring of boundaries in the doctor–patient relationship. **Lancet Oncology**, Vol 15 December 2014 (IF 36.4)
 96. Grisendi G, Spano C, D'souza N, Rasini V, Veronesi E, Prapa M, Petrachi T, Piccinno S, Rossignoli F, Burns J S, Fiorcari S, Granchi D, Baldini N, Horwitz E, **Guarneri V**, Conte P, Paolucci P, Dominici M. Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas. **Stem Cells**, 2015 Mar;33(3):859-69. doi: 10.1002/stem.1903 (IF 5.587)
 97. Lucarini V, Madrigali S, Lugli R, Maur M, Bertolini F, Fontana A, Masini C, **Guarneri V**, Conte PF, Dominici M. Pazopanib-Induced Heart Failure In A Metastatic Sarcoma Patient: Between Reversible Side Effect and Efficacy. **American Journal of Cancer Case Reports**. September 12, 2014 | Volume 2 | Issue 2 (Article ID 201400410)
 98. Grisendi G, Finetti E, Manganaro D, Cordova N, Montagnani G, Spano C, Prapa M, **Guarneri V**, Otsuru S, Horwitz EM, Mari G, Dominici M. Detection of microparticles from human red blood cells by multiparametric flow cytometry. **Blood Transfus**. 2014 Oct 23:1-7 (IF 2.138)
 99. Dieci MV, Piacentini F, Dominici M, Omarini C, Goubar A, Ficarra G, Conte P, **Guarneri V**. Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact. **Anticancer Res**. 2014 Jul;34(7):3657-62. (IF 1.865)
 100. Falci C, Dieci MV, Guarneri V, Soldà C, Bria E, Tortora G, Conte P. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. **Expert Rev Anticancer Ther**. 2014 Sep;14(9):1041-50. (IF 2.347)
 101. Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. **The Oncologist**. 2014 Aug;19(8):805-13. (IF 5.306)
 102. Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D'Amico R. Trastuzumab-containing regimens for metastatic breast cancer. **Cochrane Database Syst Rev**. 2014 Jun 12;6:CD006242. (IF 6.754)
 103. Bria E, Carbognin L, Furlanetto J, Pilotto S, Bonomi M, Guarneri V, Vicentini C, Brunelli M, Nortilli R, Pellini F, Sperduti I, Giannarelli D, Pollini GP, Conte P, Tortora G. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. **Cancer Treat Rev**. 2014 Aug;40(7):847-56. (IF 8.122)
 104. Califano R, Karamouzis MV, Banerjee S, de Azambuja E, **Guarneri V**, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, S. Postel-Vinay S, Preusser M, Porcu L, Torri V. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee. **Lung Cancer**, 2014 Jul;85(1):74-80. (IF 4.486)
 105. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte PF, **Guarneri V**, Ficarra G, Mathieu MC, Delaloge S, Andre F, Curigliano G. Prognostic value of tumor infiltrating lymphocytes (TILs) on residual disease after primary chemotherapy for triple-negative breast cancer (TNBC) patients. **Ann Oncol**, 2014 Mar;25(3):611-8. (IF 13.926)
 106. **Guarneri V**, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte PF. Double-blind, placebo-controlled, multicenter randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, HER2-negative, operable breast cancer. **J Clin Oncol**, 2014 Apr 1;32(10):1050-7 (IF: 26.303)

107. **Guarneri V**, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2 positive breast cancer patients. **Ann Oncol**, 2013 Dec;24(12):2990-4. (IF 13.926)
108. **Guarneri V**, Dieci MV, Conte PF. Relapsed triple-negative breast cancer: challenges and treatment strategies. **Drugs**, 2013 Aug;73(12):1257-65 (IF 4.69)
109. Collovà E, Ciccarese M, Di Maio M, Fabi A, Generali D, **Guarneri V**, La Verde N, Moscetti L, Salesi N, Scandurra G. l'attualità nella pratica clinica del trattamento del carcinoma della mammella avanzato. **Expert Review of Anticancer Therapy**, Special Issue n1 , 2013
110. Dieci MV, **Guarneri V**, Conte PF. The Future of Chemotherapy in the Era of Personalized Medicine. **Current Breast Cancer Reports** 2013, 5 Issue 1, 57-68
111. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettell S, Dominici M, Conte PF, **Guarneri V**. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis. **Ann Oncol** 2013 Jan;24(1):101-8 (IF 13.926)
112. Cortesi L, Marcheselli L, **Guarneri V**, Cirilli C, Braghiroli B, Toss A, Sant M, Ficarra G, Conte PF, Federico M. Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. **Int J Cancer**. 2013 Jan 15;132(2):E58-65. (IF 7.363)
113. **Guarneri V**, Conte P. The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer. **Clin Breast Cancer** 2012 Jun;12(3):157-66 (IF: 2.703)
114. **Guarneri V**, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte PF. Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study. **J Clin Oncol**, 2012 Jun 1;30(16):1989-95 (IF: 26.303)
115. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, **Guarneri V**, D'Amico R. Trastuzumab containing regimens for early breast cancer. **Cochrane Db Syst Rev**, 2012 Apr 18;4:CD006243 (IF: 6.754)
116. **Guarneri V**, Dieci MV, Conte P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. **Expert Opin Pharmacother**. 2012 Feb;13(3):395-406. (IF: 3.475)
117. **Guarneri V**, Conte PF. A guided choice for treatment of hormone receptor-positive advanced breast cancer. **Hot Topics Oncol** 2011;5(8):15-20
118. Dieci MV, Barbieri E, Bettelli S, Piacentini F, Omarini C, Ficarra G, Balduzzi S, Dominici M, Conte P, **Guarneri V**. Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. **J Clin Pathol**. 2012 Jun;65(6):503-6 (IF: 2.894)
119. **Guarneri V**, Barbieri E, Conte PF. Biomarkers predicting clinical benefit: facts or fiction? **J Natl Cancer Inst Monogr** 2011;2011(43):63-6.
120. Grisendi G, Bussolari R, Veronesi E, Piccinno S, Burns JS, De Santis G, Loschi P, Pignatti M, Di Benedetto F, Ballarin R, Di Gregorio C, **Guarneri V**, Piccinini L, Horwitz EM, Paolucci P, Conte P, Dominici M. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. **Am J Cancer Res**. 2011;1(6):787-805. (IF 3.988)
121. Alvarez R, **Guarneri V**, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte PF, Hortobagyi GN. Bevacizumab Treatment for Advanced Breast Cancer. **The Oncologist**, 2011;16(12):1684-97 (IF: 5.306)
122. F Piacentini, G Rossi, C Casali, A Caldioli, E Barbieri, **V Guarneri**. Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications. **Lung Cancer**, 2011 Oct;74(1):145-8 (IF: 4.486)
123. **Guarneri V**, Pecchi A, Piacentini F, Barbieri E, Ficarra G, Tazzioli G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Torricelli P. Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer. **Ann Surg Oncol**, 2011 Aug;18(8):2150-7. (IF: 3.857)
Curriculum vitae of Valentina Guarneri

124. **Guarneri V**, Barbieri E, Dieci MV, Piacentini F, Conte PF. Timing for starting second line therapy in recurrent ovarian cancer. **Expert Rev. Anticancer Ther**, 2011 Jan;11(1):49-55. (IF: 2.347)
125. **Guarneri V**, Barbieri E, Dieci MV, Piacentini F, Conte PF. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. **Cancer Treat Rev** 2010 Nov;36S3:S62-S66. (IF: 8.122)
126. **Guarneri V**, Miles D, Robert N, Diéras V, Glapsy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte PF. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. **Breast Cancer Res Treat**, 122(1):181-8, 2010. (IF: 3.606)
127. **Guarneri V**, Barbieri E, Piacentini F, Giovannelli S, Ficarra G, Frassoldati A, Maiorana A , D'Amico R, Conte PF. Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single Institution analysis. **Int J Biol Marker** 25(2):104-11. 2010 (IF: 1.449)
128. **Guarneri V**, Barbieri E, Piacentini F, Conte PF Achievements and unmet needs in the management of advanced ovarian cancer. **Gynecol Oncol** 117(2):152-8 2010 (IF: 4.54)
129. **Guarneri V**. Letrozole plus lapatinib for postmenopausal patients with HR+/HER2+ breast cancer. **Expert Rev. Anticancer Ther**, Vol. 9, No. 11, 1549-1557 2009 (IF: 2.347)
130. Frassoldati A, **Guarneri V**, Conte PF. Clinical relevance of endocrine therapy-induced changes in lipid metabolism in breast cancer patients. **Cancer Biol. Ther.** 2009 Aug;8(15):1456-8. (IF: 3.373)
131. **Guarneri V**, Conte PF. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. **The Oncologist** 2009 Jul;14(7):645-56 (IF: 5.306)
132. Conte PF, **Guarneri V**. Triple-negative breast cancer: current management and future options. *Eur J Cancer Supp* 2009, 7(1): 14-18
133. **Guarneri V**, Piacentini F, Ficarra G , Frassoldati A, D'Amico R, Giovannelli S, Maiorana A , Jovic G, Conte PF. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. **Ann Oncol**, 2009 Jul;20(7):1193-8 (IF 13.926)
134. **Guarneri V**, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, Barbieri E, Dieci MV, D'Amico R, Jovic G, Conte PF. Comparison of HER-2 and Hormone Receptor expression in primary breast cancer and asynchronous paired metastases: impact on patients' management. **The Oncologist**, 13:838-44, 2008 (IF: 5.306)
135. **Guarneri V**, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A, Bertetto O, Cascinu S, Cognetti F, Di Leo A, Pronzato P, Conte PF. Multicentric, randomised, phase III trial of 2 different adjuvant chemotherapy regimens plus 3 versus 12 months of trastuzumab in HER2 positive breast cancer patients (Short-HER trial, NCT00629278). **Clin Breast Cancer** 8:453-6, 2008 (IF: 2.703)
136. **Guarneri V**, Frassoldati A, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte PF Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. **Clin Breast Cancer**, 8: 192-194, 2008 (IF: 2.703)
137. Frassoldati A, **Guarneri V**, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte PF. Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB). **Clin Breast Cancer**, 8:97-100, 2008 (IF: 2.703)
138. **Guarneri V**, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte PF. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. **Breast Cancer Res Treat**, 110:127-34, 2008. (IF 3.605)
139. Hoff AO, Toth B, Altundag K, Johnson M, Warneke C, Nooka A, Sayegh G, **Guarneri V**, Desrouleaux K, Cui J, Adamus A, Gagel RF and Hortobagyi GN. The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw or Maxilla in a Large Population of Cancer Patients Treated with Intravenous Bisphosphonates. **J Bone Miner Res.** 2008 Jun;23(6):826-36. (IF: 6.314)

140. Conte PF, **Guarneri V**, Bengala C. Evolving nonendocrine therapeutic options for metastatic breast cancer: How adjuvant chemotherapy influences treatment. **Clin Breast Cancer** 2007, vol 7, No 11, 841-849 (IF: 2.703)
141. Thomas E, Tabernero J, Fornier M, Conte PF, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, **Guarneri V**, Poulart V, Klimovsky J, Lebwohl D, Martin M. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. **J Clin Oncol** 2007, Aug 10;25 (23):3399-406 (IF: 26.303)
142. Conte PF, Bengala C, **Guarneri V**. Controversies of chemotherapy for the treatment of metastatic breast cancer. **Eur J Cancer Supp** 2007 s5 (1):11-16
143. Cristofanilli M, Broglio KR, **Guarneri V**, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau S, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V. Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. **Clin Breast Cancer**. 2007 Feb;7(6):471-9. (IF: 2.703)
144. **Guarneri V** and Conte PF. Bone health: new horizons in the prevention of cancer-treatment induced bone loss and management of bone metastases. **EJHP Practice** 2006; 6: 69 -70
145. Gonzalez-Angulo AM, **Guarneri V**, Gong Y, Cristofanilli M, Morales-Vasquez F, Sneige N, Hortobagyi GN, Esteva FJ. Downregulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 Might Correlate with Poor Disease-Free and Overall Survival in Inflammatory Breast Cancer. **Clin Breast Cancer**. 2006 Oct;7(4):326-330. (IF: 2.703)
146. Guarneri V, Frassoldati A, Giovannelli S, Borghi F, Conte PF. Primary Systemic Therapy for Operable Breast Cancer: A Review of Clinical Trials and Perspectives. **Cancer Lett**. 2007, 248:175-85 (IF 6.491)
147. **Guarneri V**, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. **J Clin Oncol** 2006, 24: 4107-15 (IF: 26.303)
148. Maur M, **Guarneri V**, Frassoldati A, Conte PF: Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out. **Ann Oncol** 2006, 17 Suppl 5:v158-v164 (IF: 13.926)
149. **Guarneri V**, Giovannelli S, Conte PF: Bisphosphonates in the treatment of metastatic bone disease from solid tumors. **Supp Pall Cancer Care** 2006, 2: s37-s41
150. **Guarneri V**, Cristofanilli M: Clinical utility of measuring circulating tumor cells in metastatic breast cancer. **Clin Breast Cancer** 2006, 7(1):85-6. (IF: 2.703)
151. Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, Martino M, Rosti G, Danova M, Bregni M, Jovic G, **Guarneri V**, Maur M, Conte PF on behalf of Gruppo Italiano Trapianto Midollo Osseo (GITMO) group: Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. **Br J Cancer** 2006, 94 (7):1016-20. (IF: 5.922)
152. **Guarneri V**, Broglio K, Kau S, Cristofanilli M, Buzdar A U, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi G N, Gonzalez-Angulo A M: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. **J Clin Oncol**. 2006; 24:1037-1044 (IF: 26.303)
153. **Guarneri V**, Donati S, Giovannelli S, Nicolini M, D'Amico R, Conte P F: Renal Safety and Efficacy of Intravenous Bisphosphonates in Patients With Skeletal Metastases Treated for up to Ten Years. **The Oncologist** 2005;10:842-8 (IF: 5.306)
154. Frassoldati A, Maur M, **Guarneri V**, Nicolini M, Conte PF. Predictive value of biological parameters for primary chemotherapy in operable breast cancer. **Clin Breast Cancer** 2005; 6: 315-324 (IF: 2.703)
155. Conte PF, Donati S, Gennari A, **Guarneri V**, Orlandini C, Rondini M, Roncella M, Marini L, Collecchi P, Viacava P, Naccarato AG, Degli Esposti R, Bonardi S, Bottini A, Saracchini S, Tumolo S, Gullo G, Santoro A, Crino L: Primary chemotherapy with Gemcitabine, Epirubicin and Taxol (GET) in operable breast cancer: a phase II study. **Br J Cancer**, 2005 93: 406-411 (IF: 5.922)
156. Bengala C, **Guarneri V**, Giovannetti E, Lencioni M, Fontana E, Mey V, Fontana A, Boggi U, Del Chiaro M, Danesi R, Ricci S, Mosca F, Del Tacca M, Conte PF. Prolonged fixed dose rate infusion of gemcitabine with autologous hemopoietic support in advanced pancreatic adenocarcinoma. **Br J Cancer**, 2005 93: 35-40 (IF:5.922)

157. Bengala C, **Guarneri V**, Ledermann J, Rosti G, Wandt H, Lotz J-H, Cure JH, Orlandini C, Ferrante P, Conte PF, Demirer T on behalf of the Solid Tumor Working Party of the EBMT: High-dose chemotherapy with autologous hemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). **Bone Marrow Transplant**, 2005 36:25-31. (IF: 4.497)
158. Dominici M, **Guarneri V**, Cafarelli L, Conte PF. Le Cellule Mesenchimali Staminali: un emergente nuovo approccio per la terapia cellulare in campo oncologico. **Trends in Medicine** 2004 4:4, 341-348
159. Conte PF, and **Guarneri V**. Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens. **The Oncologist**. 9 Suppl 4:28-37, 2004 (IF: 5.306)
160. Conte PF, **Guarneri V**, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Gallo L, Mammoliti S, Carnino F, Vesentini L, Giannesi P, Di Marsico R, Costantini M, Beccaro M, Moyano A, Baldini E. Concomitant versus sequential administration of epirubicin and paclitaxel as first line therapy in metastatic breast cancer: results from the GONO randomized trial. **Cancer** 101 (4): 704-712, 2004 (IF: 6.537)
161. **Guarneri V**, Bengala C, Orlandini C, Gennari A, Donati S, Campani D, Collecchi P, Maur M, Bevilacqua G, Conte PF. Her2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high dose chemotherapy and autologous stem cell support. **Bone Marrow Transplant**. 34(5):413-7, 2004 (IF: 4.497)
162. **Guarneri V**, and Conte PF. The curability of breast cancer and the treatment of advanced disease. **Eur J Nucl Med Mol Imaging**. 31 Suppl 1: S149-61, 2004 (IF: 7.704)
163. Gennari A, Bruzzi P, Orlandini C, Salvadori B, Donati S, Landucci E, Guarneri V, Rondini M, Ricci S, Conte PF: Activity of first line epirubicin and paclitaxel in metastatic breast cancer is independent from type of adjuvant therapy. **Br J Cancer** 90(5):962-7, 2004. (IF: 5.922)
164. Bengala C, Danesi R, **Guarneri V**, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, Innocenti F, Del Tacca M, Mariani M, Conte PF. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. **Bone Marrow Transplant**. 31(4):275-80, 2003 (IF: 4.497)
165. Gennari A, **Guarneri V**, Landucci E, Orlandini C, Rondini M, Salvadori B, Ricci S, Conte PF. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. **Clin Breast Cancer**. 3(5):346-52, 2002 (IF: 2.703)
166. Conte P, Gennari A, Landucci E, **Guarneri V**, Donati S, Salvadori B, Bengala C, Orlandini C. New combinations with epirubicin in advanced breast cancer. **Oncology** 15 (5 Suppl 7):24-7, 2001 (IF: 3.398)
167. Conte P, Gennari A, **Guarneri V**, Landucci E, Donati S, Salvadori B, Bengala C, Orlandini C, Baldini E. Epirubicin/taxane combinations in breast cancer: experience from several Italian trials. **Oncology** 15 (5 Suppl 7):21-31, 2001 (IF: 3.398)
168. Bengala C, Pazzagli I, Innocenti F, Donati S, Favre C, Menconi MC, Greco F, Danesi R, Orlandini C, **Guarneri V**, Del Tacca M, Conte PF. High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). **Ann Oncol**. 12(1):69-74, 2001 (IF 13.926)

I authorize the use of my personal data in compliance with the Italian legislative decree 196/03

Prof. Valentina Guarneri
Padova, January 2021

